Answers are grounded in this paper and cite their sources.
SU achieves cancer-specific and overall survival comparable to RNU, even in high-grade ureteral UTUC, while significantly improving postoperative renal function. However, it necessitates multidisciplinary management of intravesical recurrence risk. Validation of molecular predictors and prospective trials in advanced disease are essential to further expand and validate the therapeutic landscape of SU.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: